These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1142 related articles for article (PubMed ID: 26343949)
1. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors. Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362 [TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF. Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301 [TBL] [Abstract][Full Text] [Related]
4. [Randomized clinical study for two types of recombinant human granulocyte colony-stimulating factor mobilizing peripheral blood and bone marrow stem cells in patients receiving allogeneic hematopoietic stem cell transplantation]. Zhang XH; Huang XJ; Liu DH; Liu KY; Han W; Chen H; Wang FR; Chen YH; Wang JZ; Zhao T; Wang Y; Xu LP Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2116-9. PubMed ID: 20058615 [TBL] [Abstract][Full Text] [Related]
5. Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation. Shahzad M; Amin MK; Bellman P; Al-Ramahi J; Noor J; Vyas A; Mahmoudjafari Z; McGuirk M; DeJarnette S; Ahmed N; Abdallah AO; Shune L; Singh AK; McGuirk JP; Abhyankar S; Mushtaq MU Transfusion; 2024 Aug; 64(8):1402-1406. PubMed ID: 38847196 [TBL] [Abstract][Full Text] [Related]
6. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684 [TBL] [Abstract][Full Text] [Related]
7. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors. Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967 [TBL] [Abstract][Full Text] [Related]
9. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. Engelhardt M; Bertz H; Afting M; Waller CF; Finke J J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272 [TBL] [Abstract][Full Text] [Related]
10. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236 [TBL] [Abstract][Full Text] [Related]
11. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation. Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941 [TBL] [Abstract][Full Text] [Related]
12. Is split-dose better than single-dose? Results of Turkish Stem Cell Coordination Center (TURKOK) donors in the era of rising biosimilar G-CSF. Pınar İE; Özkocaman V; Özkalemkaş F; Durgut H; Dakiki B; Ersal T; Gürsoy V; Yalçın C; Orhan B; Candar Ö; Ali R J Clin Apher; 2022 Oct; 37(5):430-437. PubMed ID: 35689647 [TBL] [Abstract][Full Text] [Related]
14. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience. Islami MM; Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh A; Alamoudi S; Alzahrani AA Ann Transplant; 2023 Mar; 28():e938585. PubMed ID: 36864713 [TBL] [Abstract][Full Text] [Related]
16. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®). Antelo ML; Zabalza A; Sánchez Antón MP; Zalba S; Aznar M; Mansilla C; Ramírez N; Olavarría E J Clin Apher; 2016 Feb; 31(1):48-52. PubMed ID: 26011178 [TBL] [Abstract][Full Text] [Related]
17. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study. Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397 [TBL] [Abstract][Full Text] [Related]
18. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies. Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507 [TBL] [Abstract][Full Text] [Related]
19. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Schmitt M; Xu X; Hilgendorf I; Schneider C; Borchert K; Gläser D; Freund M; Schmitt A Bone Marrow Transplant; 2013 Jul; 48(7):922-5. PubMed ID: 23318540 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]